Simona Rizzato

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

Giuseppe Lombardi, Gian Luca De Salvo, Alba A. Brandes et al. · The Lancet Oncology · 2018 · 367 citations

Neuro-oncology, Medicine, Relapsed Glioblastoma +10

A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib

Alessandra Santangelo, Marzia Rossato, Giuseppe Lombardi et al. · Neuro-Oncology · 2020 · 76 citations · Full text

Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial

Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino et al. · Journal of Thoracic Oncology · 2022 · 63 citations · Full text

Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology)

Giuseppe Lombardi, Andrea Pace, Francesco Pasqualetti et al. · Journal of Neuro-Oncology · 2015 · 43 citations

Neuro-oncology, Glioma, Radiation Therapy +10

MGMT Pyrosequencing-Based Cut-Off Methylation Level and Clinical Outcome in Patients with Glioblastoma Multiforme

Lorena Gurrieri, Elisa De Carlo, Lorenzo Gerratana et al. · Future Oncology · 2018 · 39 citations